[1] Logghe P, Verlinde R, Bouttens F, et al. Long term outcome and side effects in patients receiving low-dose I125 brachytherapy:a retrospective analysis[J]. Int braz jurol, 2016, 42(5):906-917. [2] Pons-Llanas O, Roldan-Ortega S, Celada-Alvarez F, et al. Permanent seed implant brachytherapy in low-risk prostate cancer:Preoperative planning with 145Gy versus real-time intraoperative planning with 160Gy[J]. ReportsofPracticalOncology & Radiotherapy, 2018, 23(4):290-297. [3] Wang W,Liu Z H,Zhu J R,et al. Brachytherapy with iodine 125 seed for bone metastases[J]. J Can Res Ther,2017,13(5):742-747. [4] Huang H, Xu S N, Li F S, et al. Clinical application of computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases[J]. Eur J Med Res, 2016, 21:18. [5] 侯帅,张辰宇,陶冶,等.125I粒子联合手术治疗口腔颌面部腺样囊性癌的疗效观察[J].解放军医学院学报,2016,37(6):564-566. [6] Zhang Q Z, Zhang K Y, Xie B, et al. Analysis of curative effect of I 125Implantation combined with radiofrequency ablation in treating bone metastases[J]. Journal of Bone Oncology, 2018, 11(1):23-26. [7] Huang M W, Wu W J, Lv X M, et al. The role of 125I interstitial brachytherapy for inoperable parotid gland carcinoma[J]. Brachytherapy, 2018, 17(1):244-249. [8] 唐富龙,张宏涛,于慧敏,等.放射性125I粒子平面布源剂量学的分布研究[J].现代肿瘤医学,2015,23(3):409-412. [9] 何丽娟,殷春许,张岭,等.125I粒籽植入放射工作人员受照剂量评估[J].中国辐射卫生,2019,28(2):139-142,147. [10] 刘亚洲,袁成,施林心,等.放射性粒子植入技术治疗恶性肿瘤进展[J].中国辐射卫生,2018,27(4):390-394. [11] 张灶钦,傅强,耿继武,等.125I粒籽植入治疗辐射防护及关键控制技术探讨[J].中国辐射卫生,2018,27(2):102-105. [12] 王俊杰,田素青,李金娜,等.放射性125I粒子平面永久插植布源剂量分布研究[J].中国微创外科杂志,2005,11(12):1061-1062. [13] 王娟,王绍其,徐建彬,等.125I粒子不同分布组织间植入对荷人胃癌裸鼠移植瘤疗效的影响[J].中华核医学杂志,2008,28(5):313-316.